Please login to the form below

Not currently logged in
Email:
Password:

Hookipa Biotech appoints new global head of research and development

Dr Igor Matushansky joins the firm from Daiichi Sankyo

Dr Igor Matushansky

Hookipa Biotech has appointed Dr Igor Matushansky as its global head, research and development in a role that focuses on strategic priorities.

Previously global head of translational development for oncology at Daiichi Sankyo, Matushansky has experience in early oncology therapeutic programmes, strategy and development.

He said: “It’s an exciting time to join the Hookipa team and I am very eager to share my experience in drug development to further its mission to help patients.”

Matushansky has also previously worked for Novartis’ oncology translational medicine unit as clinical programme lead.

Joern Aldag, CEO at Hookipa Biotech, said: “Dr Matushansky’s valuable experience heading up R&D units at big pharma companies coupled with his significant immuno-oncology expertise will be transformative to Hookipa as we expand our company from prophylactic to therapeutic immuno-oncology focused therapies.

“I look forward to working together to achieve our goals and strategic priorities for 2017 and beyond.”

22nd March 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics